A Comprehensive Review on Cardiovascular Diseases: Epidemiology, Pathophysiology, and Emerging Therapeutic Strategies

Cardiovascular diseases (CVDs) constitute the leading cause of mortality and morbidity globally, representing a major public health challenge in both developed and developing nations. The increasing prevalence of CVD is strongly associated with rapid urbanization, sedentary lifestyle, unhealthy dietary habits, and an aging population. This review provides a comprehensive and updated overview of cardiovascular diseases, focusing on epidemiology, pathophysiological mechanisms, risk factors, current treatment modalities, emerging therapeutic strategies, and recent clinical trial evidence. The pathogenesis of CVD is multifactorial, involving endothelial dysfunction, lipid accumulation, chronic inflammation, and thrombogenesis, ultimately leading to atherosclerosis and its complications. Conventional pharmacological interventions, including antihypertensive agents, lipid-lowering drugs, antiplatelet agents, and anticoagulants, remain the cornerstone of management. However, novel therapeutic approaches such as PCSK9 inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and gene-based therapies have demonstrated significant clinical benefits in recent studies. Additionally, advancements in artificial intelligence and precision medicine are revolutionizing early diagnosis and individualized treatment strategies. This review aims to highlight recent developments and provide insights into future directions for effective prevention and management of cardiovascular diseases.

cardiovascular disease; Atherosclerosis; Hypertension

1. World Health Organization. Cardiovascular diseases (CVDs). Geneva: WHO; 2023. [Google Scholar] [Crossref]

2. World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO; 2022. [Google Scholar] [Crossref]

3. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India. Circulation. 2016;133(16):1605–20. [Google Scholar] [Crossref]

4. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction. Lancet. 2004;364(9438):937–52. [Google Scholar] [Crossref]

5. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases. J Am Coll Cardiol. 2020;76(25):2982–3021. [Google Scholar] [Crossref]

6. GBD 2019 Diseases and Injuries Collaborators. Global burden of disease study 2019. Lancet. 2020;396:1204–22. [Google Scholar] [Crossref]

7. Gupta R, Mohan I, Narula J. Trends in cardiovascular risk factors in India. J Am Coll Cardiol. 2016;68(25):2745–56. [Google Scholar] [Crossref]

8. Barquera S, Pedroza-Tobías A, Medina C, et al. Global overview of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–38. [Google Scholar] [Crossref]

9. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians. JAMA. 2007;297(3):286–94. [Google Scholar] [Crossref]

10. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74. [Google Scholar] [Crossref]

11. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26. [Google Scholar] [Crossref]

12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. [Google Scholar] [Crossref]

13. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of plaque rupture. J Am Coll Cardiol. 2006;47(8):C13–8. [Google Scholar] [Crossref]

14. Braunwald E. Heart failure pathophysiology. Circulation. 2013;128(20):2215–23. [Google Scholar] [Crossref]

15. Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on prevention of cardiovascular disease. Circulation. 2019;140(11):e596–646. [Google Scholar] [Crossref]

16. Grundy SM. Cholesterol and coronary heart disease. JAMA. 1998;279(20):1641–7. [Google Scholar] [Crossref]

17. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002;287(19):2570–81. [Google Scholar] [Crossref]

18. Ambrose JA, Barua RS. Smoking and cardiovascular disease. J Am Coll Cardiol. 2004;43(10):1731–7. [Google Scholar] [Crossref]

19. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease. Circulation. 2006;113(6):898–918. [Google Scholar] [Crossref]

20. Mozaffarian D, Wilson PW, Kannel WB. Beyond cholesterol: diet and CVD. Circulation. 2008;117(24):3141–53. [Google Scholar] [Crossref]

21. Khera AV, Kathiresan S. Genetics of coronary artery disease. Cell. 2017;171(1):44–56. [Google Scholar] [Crossref]

22. James PA, Oparil S, Carter BL, et al. Hypertension management guidelines. JAMA. 2014;311(5):507–20. [Google Scholar] [Crossref]

23. Baigent C, Blackwell L, Emberson J, et al. Statins and cardiovascular risk reduction. Lancet. 2010;376(9753):1670–81. [Google Scholar] [Crossref]

24. Antithrombotic Trialists’ Collaboration. Aspirin in prevention of vascular disease. Lancet. 2009;373(9678):1849–60. [Google Scholar] [Crossref]

25. Ruff CT, Giugliano RP, Braunwald E, et al. Anticoagulants in atrial fibrillation. N Engl J Med. 2014;371(10):972–83. [Google Scholar] [Crossref]

26. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition in heart failure. N Engl J Med. 2014;371(11):993–1004. [Google Scholar] [Crossref]

27. Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012;9(6):360–70. [Google Scholar] [Crossref]

28. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes (FOURIER trial). N Engl J Med. 2017;376(18):1713–22. [Google Scholar] [Crossref]

29. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin and cardiovascular outcomes (EMPA-REG). N Engl J Med. 2015;373(22):2117–28. [Google Scholar] [Crossref]

30. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes. N Engl J Med. 2016;375(4):311–22. [Google Scholar] [Crossref]

31. Musunuru K. Gene therapy for cardiovascular disease. Nat Rev Cardiol. 2017;14(12):731–47. [Google Scholar] [Crossref]

32. Madonna R, Van Laake LW, Davidson SM, et al. Stem cell therapy in heart disease. Eur Heart J. 2016;37(23):1789–98. [Google Scholar] [Crossref]

33. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in lipid lowering (siRNA therapy). N Engl J Med. 2017;376(15):1430–40. [Google Scholar] [Crossref]

34. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. [Google Scholar] [Crossref]

35. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. [Google Scholar] [Crossref]

36. Johnson KW, Torres Soto J, Glicksberg BS, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668–2679. [Google Scholar] [Crossref]

37. Keesara S, Jonas A, Schulman K. Covid-19 and health care’s digital revolution (telemedicine). N Engl J Med. 2020;382(23):e82 [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities